liraglutide [aapp, horm, phsu]
treatment [ftcn]
Pre-diabetes NOS [dsyn]
Overweight [sosy]
Obesity [dsyn]
Clozapine [orch, phsu]
olanzapine [orch, phsu]
treated [topp]
Patients [podg]
Schizophrenia [mobd]
Spectrum [qnco]
Disorder [dsyn]
Randomized Clinical Trial [inpr, resa]
Compared [acty]
General Population [popg]
Patients [podg]
Schizophrenia [mobd]
Fold [spco]
Mortality rate [qnco]
Cardiovascular disease [dsyn]
Previous [tmco]
interventions [hlca]
Design [acty]
Antipsychotic [phsu]
Induced [ftcn]
Weight Gain [fndg]
Disturbance [qlco]
Reported [inpr]
Limited [ftcn]
effects [qlco]
objectives [inpr]
effects [qlco]
Glucagon-like Peptide-1 Receptor Agonist [phsu]
liraglutide [aapp, horm, phsu]
Added [ftcn]
Clozapine [orch, phsu]
olanzapine [orch, phsu]
treatment [ftcn]
schizophrenia disorder [mobd]
Spectrum [qnco]
Design [acty]
setting [ftcn]
participants [popg]
thi [euka]
Randomized Clinical Trial [inpr, resa]
DOUBLE BLIND [resa]
Sites [spco]
Denmark [geoa]
eligible [idcn]
participants [popg]
schizophrenia disorder [mobd]
Spectrum [qnco]
randomized [resa]
liraglutide [aapp, horm, phsu]
placebo [topp]
participants [popg]
Received [qlco]
Stable [qlco]
treatment [ftcn]
Clozapine [orch, phsu]
olanzapine [orch, phsu]
Overweight [sosy]
Obese [dsyn]
Pre-diabetes NOS [dsyn]
Collected [idcn]
interventions [hlca]
treatment [ftcn]
weeks [tmco]
Daily [tmco]
Subcutaneous injection [ftcn]
liraglutide [aapp, horm, phsu]
placebo [topp]
Trial drug [phsu]
therapy [ftcn]
Titrate [hlca]
weeks [tmco]
Study [mnob]
Main [qlco]
Measure [qnco]
Primary Endpoint [irda]
Glucose tolerance [phsf]
Estimated [qnco]
75 g [qnco]
Oral Glucose Tolerance Test [diap]
secondary [neop]
End Point [qlco]
included [ftcn]
Body Weight [orga]
Parameters [fndg]
Patients [podg]
Randomization [resa]
Men [popg]
Women [popg]
included [ftcn]
Efficacy [qlco]
Age [orga]
Body Mass Index [diap]
Calculated [ftcn]
weight [orga]
kilograms [qnco]
divided [ftcn]
Height [orga]
Meters [medd]
Square [spco]
liraglutide [aapp, horm, phsu]
placebo [topp]
Group [idcn]
Characteristics [qlco]
SD [fndg]
Age [orga]
Men [popg]
Group [idcn]
SD [fndg]
Body Mass Index [diap]
randomized [resa]
participants [popg]
COMPLETED [qlco]
Trial [resa]
Glucose tolerance [phsf]
Improved [qlco]
liraglutide [aapp, horm, phsu]
Group [idcn]
Compared [acty]
placebo [topp]
Group [idcn]
P NOS [aapp, imft]
liraglutide [aapp, horm, phsu]
treated [topp]
participants [popg]
normal glucose [fndg]
Tolerance [fndg]
Compared [acty]
placebo [topp]
treated [topp]
participants [popg]
P NOS [aapp, imft]
Needed [qlco]
Body Weight [orga]
Decreased [qnco]
liraglutide [aapp, horm, phsu]
Compared [acty]
placebo [topp]
KG [geoa]
KG [geoa]
reductions [npop]
Waist Circumference [clna]
2-3 [resa]
Systolic blood pressure [clna]
Visceral Fat [tisu]
40 g [qnco]
Low density lipoprotein [aapp, bacs, lipd]
Occurred [acty]
liraglutide [aapp, horm, phsu]
Compared [acty]
placebo [topp]
adverse events [fndg]
liraglutide [aapp, horm, phsu]
Affected [ftcn]
Gastrointestinal Tract [bdsy]
Conclusions [idcn]
Relevance [qlco]
liraglutide [aapp, horm, phsu]
Improved [qlco]
Glucose tolerance [phsf]
Body Weight [orga]
Disturbance [qlco]
Patients [podg]
schizophrenia disorder [mobd]
Spectrum [qnco]
treated [topp]
Clozapine [orch, phsu]
olanzapine [orch, phsu]
